Entero Therapeutics (NASDAQ: ENTO) Just Hit Our Watchlist For Monday Morning—Find Out Why

Krypton Street Announces Entero Therapeutics, Inc. (Nasdaq: ENTO) as its Next Potential Breakout Idea This Monday. Entero Therapeutics, Inc. (Nasdaq: ENTO) comes backed by several potential catalysts including:  Low Float, Big Swing Potential: With fewer than 4.7M shares available, (ENTO) has seen sharp moves, including recent 60%, 72%, and 124% swings. Tiny Market Cap: At just $2.35M, even a minor breakthrough in its late-stage pipeline could make a big impact. Advancing a Late-Stage Pipeline: (ENTO) is developing three GI treatments, including a Phase 3-ready therapy for celiac disease. Regulatory Milestones Secured: FDA Fast Track Designation and a Phase 3 trial expected in 2025 add credibility to its pipeline. Technical Momentum Building: Recently closed above its 5-day moving average, with key resistance levels ahead that could trigger further moves. Targeting High-Demand Conditions: With no FDA-approved treatments for celiac disease and few options for gastroparesis and pancreatic insufficiency, (ENTO) is addressing significant medical needs. Still Flying Under the Radar: (ENTO) remains largely undiscovered—but history shows that it doesn't last forever. March 2, 2025 Dear Reader, The biotech and pharma space moves fast—one breakthrough can take a little-known company from obscurity to the spotlight in no time. Last Monday morning, we saw it firsthand—our profile from last Sunday night surged approximately 94% shortly after the opening bell rang. And now, we’re keeping an eye on another name with similar characteristics. Enter Entero Therapeutics, Inc. (Nasdaq: ENTO). This late-stage clinical biopharmaceutical company is developing targeted, non-systemic therapies for serious gastrointestinal diseases, a space where countless patients continue to seek more effective treatment options. With multiple candidates in the pipeline, including a potential first-in-class oral therapy for celiac disease, Entero Therapeutics, Inc. (Nasdaq: ENTO) has positioned itself in a high-growth sector. But what really makes this one interesting? Why Entero Therapeutics, Inc. (Nasdaq: ENTO) is Topping Our Watchlist Tomorrow. With less than 4.7M shares in the float, (ENTO) has the kind of low-float structure that has the potential to move quickly if demand begins to shifts Just look at these recent moves: Approx. 60% overnight move 12/04/2024: $0.4600 → 12/05/2024: $0.7400 Approx. 72% overnight move 12/05/2024: $0.4800 → 12/06/2024: $0.8300  Approx. 124% move in under two weeks 11/27/2024: $0.4124 → 12/09/2024: $0.9260 Pair that with a tiny $2.35M market cap, and it’s clear that even a small breakthrough in their pipeline could have a big impact. Technical Indicators Show Signs of Momentum Beyond the fundamentals, Entero Therapeutics, Inc. (Nasdaq: ENTO) is also showing technical strength. Recently closed above its 5-day moving average—a short-term bullish signal that often attracts momentum traders. Key resistance levels at the 20, 50, 100, and 200-day moving averages—if broken, these could fuel further upside potential. Low float + bullish technical signals = a combination that’s caught attention before. For now, this name remains under the radar. But as history has shown—companies like this don’t stay quiet forever.) Entero Therapeutics, Inc. (Nasdaq: ENTO) is a clinical-stage biopharmaceutical company dedicated to developing targeted, non-systemic therapies for serious gastrointestinal (GI) diseases, where current treatment options remain limited. Formed through the merger of First Wave BioPharma and ImmunogenX, Entero Therapeutics, Inc. (Nasdaq: ENTO) has built a robust pipeline of late-stage clinical assets aimed at addressing significant unmet medical needs in high-value healthcare markets. Advancing a Late-Stage Pipeline in GI Health Entero Therapeutics, Inc. (Nasdaq: ENTO) is focused on three key candidates, each with the potential to redefine treatment standards for major GI conditions: Latiglutenase (Phase 3 – Celiac Disease): A first-in-class oral biotherapeutic designed to help gluten-sensitive patients by improving gluten digestion and reducing symptoms. With no FDA-approved therapies for celiac disease, Latiglutenase could be a breakthrough solution for a vast population in need of better treatment options. Capeserod (Phase 2 – Gastroparesis & GI Disorders): Originally developed by Sanofi, this 5-HT4 receptor partial agonist is being repurposed to improve gastric motility in patients with gastroparesis and other GI disorders, conditions often underserved by current treatments. Adrulipase (Phase 2 – Exocrine Pancreatic Insufficiency - EPI): A recombinant lipase enzyme designed to enhance nutrient absorption in patients with cystic fibrosis and chronic pancreatitis, offering a potentially more effective alternative to traditional pancreatic enzyme replacement therapies (PERT). Strategic Growth & Market Position With clinical trials advancing across multiple programs, Entero Therapeutics, Inc. (Nasdaq: ENTO)  is well-positioned to capitalize on high-growth GI markets. The company has already secured: ✅ FDA Fast Track Designation & Phase 3 Readiness for Latiglutenase, with pivotal trials expected to begin in early 2025. ✅ Exclusive Sanofi partnership rights for Capeserod, which could unlock new treatment pathways for gastroparesis and related GI conditions. ✅ A strong intellectual property portfolio, securing long-term market exclusivity across its pipeline assets. 7 Reasons Why Entero Therapeutics, Inc. (Nasdaq: ENTO) is Topping Our Watchlist Tomorrow Morning… 1. Low Float with Big Swings: With a float of less than 4.7M shares, (ENTO) has shown the ability to move quickly, including recent 60%, 72%, and 124% approx. swings in short time frames. 2. Tiny Market Cap, Room to Grow: At just $2.35M, even a small breakthrough in the company’s late-stage pipeline could have a significant impact. 3. Advancing a High-Potential Pipeline: The company is developing three late-stage GI treatments, including a Phase 3-ready oral therapy for celiac disease, a Phase 2 candidate for gastroparesis, and a Phase 2 enzyme therapy for exocrine pancreatic insufficiency. 4. Key Regulatory Milestones Secured: ENTO has FDA Fast Track Designation for Latiglutenase, a Phase 3 trial expected to begin in 2025, and a Sanofi-backed GI treatment moving into Phase 2 studies. 5. Technical Indicators Showing Momentum: ENTO has recently closed above its 5-day moving average, a short-term signal traders watch closely, with key resistance levels at the 20, 50, 100, and 200-day averages that could lead to further movement. 6. Addressing Unmet Needs in GI Health: With no FDA-approved treatments for celiac disease and limited options for gastroparesis and pancreatic insufficiency, ENTO is targeting high-demand medical conditions that could attract significant attention. 7. Still Under the Radar—for Now: Despite low float, bullish technicals, and a promising pipeline, ENTO remains relatively undiscovered—but history shows that companies like this don’t stay quiet forever. Consider Adding Entero Therapeutics (Nasdaq: ENTO) to Your Radar This Week… When it comes to low-float biotech names with a shot at something bigger, Entero Therapeutics (Nasdaq: ENTO) checks a lot of boxes. A tiny $2.35M market cap, a late-stage pipeline targeting high-demand GI conditions, and regulatory milestones already in place—it’s the kind of setup that tends to get noticed fast. Add in recent price swings of approx. 60%, 72%, and 124%, bullish technical indicators flashing, and a market that still hasn’t fully caught on?  Let’s just say, we’ve seen how quickly names like this can heat up. We will have all eyes on (ENTO) tomorrow morning.  Consider taking a look at (ENTO) before you call it a night.  Also, keep an eye out for my morning update.  We will be up bright and early covering (ENTO). Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: kryptonstreet.com/disclaimer/ *Media 1717 LLC has not been compensated for the March 2nd and 3rd, 2025's profile on (ENTO:US). Neither Media 1717 LLC, TD Media LLC and their member own shares of (ENTO:US).

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice